The Application of Nanobody in CAR-T Therapy

Biomolecules

Lin-Lin Li¹  Quanli Gao¹  Lu Han¹  Jishuai Zhang²  Xian-Hui Wu²  Yijin Ding²  Bingxiang Zhang²  Zongpei Song²  Chaolemeng Bao²  Ruining Zhang² 

[1] Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, China;Shenzhen Pregene Biopharma Company Ltd., Shenzhen 518118, China;

关键词: nanobody;    V_HH;    CAR-T;    BCMA;   

DOI  :  10.3390/biom11020238

来源: DOAJ

【 摘 要 】

Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks.

【 授权许可】

Unknown